UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On January 18, 2024, Tenax Therapeutics, Inc. (the “Company”) received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company’s common stock had a closing price of $1.00 or greater for the ten consecutive trading days from January 3, 2024 to January 17, 2024 and that as a result the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and that the matter is now closed.
As previously reported, on March 29, 2023, Nasdaq notified the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to the Bid Price Rule. On September 28, 2023, the Company received formal notice that Nasdaq had granted the Company’s request for an extension through March 25, 2024 to evidence compliance with the Bid Price Rule.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 19, 2024 | Tenax Therapeutics, Inc. |
| |
|
|
|
|
| By: | /s/ Christopher T. Giordano |
|
| Christopher T. Giordano |
| |
| President and Chief Executive Officer |
|
3 |
Cover |
Jan. 18, 2024 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | Tenax Therapeutics, Inc. |
Entity Central Index Key | 0000034956 |
Document Type | 8-K |
Amendment Flag | false |
Entity Emerging Growth Company | false |
Document Period End Date | Jan. 18, 2024 |
Entity File Number | 001-34600 |
Entity Incorporation State Country Code | DE |
Entity Tax Identification Number | 26-2593535 |
Entity Address Address Line 1 | 101 Glen Lennox Drive |
Entity Address Address Line 2 | Suite 300 |
Entity Address City Or Town | Chapel Hill |
Entity Address State Or Province | NC |
Entity Address Postal Zip Code | 27517 |
City Area Code | 919 |
Local Phone Number | 855-2100 |
Security 12b Title | Common Stock, $0.0001 par value per share |
Trading Symbol | TENX |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
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end
&A1PMFA,6KW)2J-]9N#W[?. '
MK6S66C&/2N>.&:5-T\3-.-;FX//X7$\/VQTOO2\B5!@XQZAG!95_\=+I=$J[
M:@_]"]D^&]GW&-/>CH=;D=FNW5;S;KCOH,%_$>%$>A@)KT@Z(N,T;FT1^6D
M7.9AM,0<]P#AX3'?#$T=JC;FNJ*A0%?:+Z4WV7%*@_MY% D?)$D32=!]O,5
MR)V/?CFMJ([2IZ-O6G(F>2V[B%M_OL)CZV4++'J5T/P]EIQP 9A 5-NV=U6W\T:T3C(OK%Y?EUZ^H_M:7@3*[/.^]:[1H!?"
1B<%9QB
MJ4!8X(8>#X9GA5@-K*/"/^NG(P50 !G(&I^<%49*137;OK^_+T[ZPB^&8FB7
M2T[%YH'/ _;Q;>>J, -7J^'GH+82-)"#4(RI BX04]4JE:WR80:))9F;0P3/
MQ6%X]RB>(ZOBI'C<6 A8W72&2'.38DI'86*YDDS)D;RO:,Z=X^-C>X(B2?%.
M)%\%6"Z5'/OC]577';$QM7@@%0U<-IL%C']:3P!'4] ER(S82Q4;A_M4SC'#
M*'\ ?HD3&/547BH)<-4V@SE0OA+TT(#R%-1C?+6@82 KXUH0CUN
M8FD^OKQ@03CFP2JT3UU-#H6=YSZW:#MOO78FI-@P >(M[?LL#7H8FBS)_\=J
M3C0YN>>>&D&D*OT"$E(8'.$'3%1>"O_VIG/1[%AO;WJ]F^L:J483(D.?>R